Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims are directionally consistent with the provided label excerpts (e.g., HDL increase, GI adverse reactions, myopathy/rhabdomyolysis, pancreatitis, gallstones as cholelithiasis risk). However, multiple specific claims are not supported or are potentially incorrect relative to the supplied label text, including the active ingredient (fenofibrate vs fenofibric acid), several proposed mechanisms, and multiple “common” adverse effects not explicitly supported as common in the label excerpts provided.
Category Scores
Accurate Statements
Antara is a brand-name medication.
Not explicitly stated in provided excerpts; however, the excerpts refer to “Antara capsules” and “Antara is indicated…”.
Antara is a prescription medication.
Not explicitly stated in provided excerpts; label excerpts are FDA prescribing information for Antara.
Antara is indicated for the adjunctive treatment with diet when diet alone is not sufficient to lower elevated triglyceride levels.
Indications and Usage [1]: “indicated as adjunctive therapy to diet… to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG ≥ 500 mg/dL).”
Antara is indicated for the treatment of hypertriglyceridemia.
Indications and Usage [1]: adjunctive therapy to diet to reduce TG levels in adults with severe hypertriglyceridemia (TG ≥ 500 mg/dL).
More serious side effects of Antara can include pancreatitis.
Warnings and Precautions [5.7]: pancreatitis reported with fenofibrates; Adverse Reactions [6.2]: “Gastrointestinal: Pancreatitis.”
More serious side effects of Antara can include muscle problems (myopathy).
Warnings and Precautions [5.3]: “Antara may cause myopathy… and rhabdomyolysis.”
More serious side effects of Antara can include rhabdomyolysis.
Warnings and Precautions [5.3]: “Antara may cause myopathy… and rhabdomyolysis.”; Adverse Reactions [6.2].
More serious side effects of Antara can include increased risk of gallstones.
Warnings and Precautions [5.5]: “Fenofibrate may increase cholesterol excretion into the bile, leading to cholelithiasis…”.
Antara increases high-density lipoprotein (HDL) cholesterol levels.
Clinical Studies [14.3]: Antara therapy “increased HDL-C”.
Unsupported Statements
Antara contains fenofibric acid, the active metabolite of fenofibrate.
The provided label excerpt says the active moiety is fenofibric acid, but it does not state that Antara “contains fenofibric acid.” Mechanistic/chemical wording in the label excerpt is about “active moiety” and conversion of fenofibrate to fenofibric acid [12.1, 12.3], not that the formulation contains fenofibric acid.
Fenofibric acid decreases triglyceride production in the body.
The provided mechanism excerpt states activation of PPAR alpha leading to increased lipolysis and elimination of triglyceride-rich particles [12.1], not specifically ‘decreases triglyceride production.’
Fenofibric acid increases the breakdown of triglycerides in the body.
The label excerpt supports increased lipolysis and elimination of triglyceride-rich particles [12.1], which is related but does not explicitly state ‘increases the breakdown of triglycerides’ as phrased.
Common side effects of Antara include diarrhea.
The provided Adverse Reactions excerpts list examples including abdominal pain, increased ALT/AST, increased CPK, constipation, and rhinitis [6.1], but do not explicitly include diarrhea as a common adverse reaction.
Common side effects of Antara include nausea.
Nausea is not explicitly listed in the provided adverse reaction examples [6.1] or postmarketing examples [6.2].
Common side effects of Antara include abdominal pain.
Abdominal pain appears in the provided examples list as an adverse reaction occurring at certain rates in trials, but the excerpt does not clearly support the categorization as “common” (e.g., the label excerpt provides “reported ≥2% and greater than placebo,” but the AI claim’s ‘common’ framing is not explicitly defined in the excerpt).
Common side effects of Antara include back pain.
Back pain is not explicitly listed in the provided adverse reaction examples [6.1] or postmarketing examples [6.2].
Common side effects of Antara include headache.
Headache is not explicitly listed in the provided adverse reaction examples [6.1] or postmarketing examples [6.2].
Common side effects of Antara include increased liver enzymes.
Increases in liver function tests were the most frequent events [6.1], which supports elevated liver enzymes as frequent, but the AI claim ties this to ‘common side effects’ without explicit mapping to the label’s phrasing; still, this is only partially supported and not clearly exact.
Antara is indicated for the treatment of hypertriglyceridemia.
The label indication is specifically adjunctive therapy to diet for adults with severe hypertriglyceridemia (TG ≥ 500 mg/dL) [1]. The AI claim omits the ‘adjunctive therapy to diet’ and the ‘severe hypertriglyceridemia’ threshold.
Contradictions
Low
AI Statement
Antara contains fenofibric acid, the active metabolite of fenofibrate.
Label Reference
Clinical Pharmacology [12.3]: fenofibrate is converted to fenofibric acid (active constituent); label discusses “active moiety,” not that Antara formulation contains fenofibric acid as the ingredient.
Important Omissions
Indication limitation: label specifies severe hypertriglyceridemia (TG ≥ 500 mg/dL) and that therapy is adjunctive to diet; also includes the second indication for reducing elevated LDL-C when recommended LDL-C lowering therapy is not possible.
Importance:
Moderate
Dosage and administration details (dose strengths 43 mg or 130 mg once daily, timing, swallowing whole, missed dose instructions, bile-acid resin separation, and dose adjustments based on renal function).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or insufficiently supported claims about multiple ‘common’ adverse effects and mechanistic statements could mislead risk expectations. Core serious risks (myopathy/rhabdomyolysis, pancreatitis, cholelithiasis) are directionally supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several safety and mechanism statements are not supported by the provided label excerpts, and adverse reaction claims use ‘common’ framing without explicit support. The indication is incomplete relative to the label’s diet adjunct and TG threshold, and it omits the LDL-C indication.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label excerpts (e.g., adjunctive diet indication and LDL-C indication; label-supported serious risks). Avoid asserting specific ‘common’ adverse events (diarrhea, nausea, back pain, headache) unless explicitly listed as common in the provided label text. Align active ingredient/active moiety wording with the label’s ‘active moiety is fenofibric acid’ and fenofibrate conversion [12.1, 12.3].